Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-299 in advanced solid tumors
NCT06650566Phase 2Recruiting
- Sponsor
- LaNova Medicines
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of LM-299 in solid tumor (advanced stage) (2 arms), sponsored by LaNova Medicines. Primary endpoints: Incidence of Dose-Limiting Toxicity at 53 weeks, Treatment-Emergent Adverse Events at 53 weeks and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
LM-299
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06650566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650566.